Companies
Moderna
BiotechnologyCambridge, MassachusettsMRNAAbout 4,700 employees
More about Moderna
Biotechnology company that develops and sells mRNA vaccines and medicines, including COVID-19 vaccines
Revenue
$1.9B
Fiscal 2025, down 40%
Employees
About 4,700
As of December 2025
Stock
MRNA
Nasdaq
Headquarters
Cambridge, Massachusetts
CEO
Stéphane Bancel
BrandsSpikevax, mNEXSPIKE, mRESVIA
Current strategyTargeting up to 10% revenue growth in 2026 through mNEXSPIKE and international partnerships while continuing to cut operating expenses
Recent workforce changesAbout 10% of the global workforce cut, announced July 2025, aiming for fewer than 5,000 employees by end of 2025
CompetitorsPfizer, BioNTech, Novavax
Checked October 11, 2026 · Sources: biospace.com, cp24.com, tickerleague.com
Be the first to post about Moderna
No one has started a discussion here yet. Yours is anonymous and appears right away, and we don’t store who wrote it.
Or follow Moderna to see the first post in your watchlist.
Follow Moderna in a feed reader, no account needed: RSS feed